Sharkey Ochoa Imogen, O'Regan Esther, Toner Mary, Kay Elaine, Faul Peter, O'Keane Connor, O'Connor Roisin, Mullen Dorinda, Nur Mataz, O'Murchu Eamon, Barry-O'Crowley Jacqui, Kernan Niamh, Tewari Prerna, Keegan Helen, O'Toole Sharon, Woods Robbie, Kennedy Susan, Feeley Kenneth, Sharp Linda, Gheit Tarik, Tommasino Massimo, O'Leary John J, Martin Cara M
TCD CERVIVA Molecular Pathology Laboratory, The Coombe Women and Infants University Hospital, D08 XW7X Dublin, Ireland.
Trinity St James Cancer Institute, Trinity College Dublin, D08 NHY1 Dublin, Ireland.
Cancers (Basel). 2022 Sep 3;14(17):4321. doi: 10.3390/cancers14174321.
Human papillomavirus (HPV) infection has been identified as a significant etiological agent in the development of head and neck squamous cell carcinoma (HNSCC). HPV's involvement has alluded to better survival and prognosis in patients and suggests that different treatment strategies may be appropriate for them. Only some data on the epidemiology of HPV infection in the oropharyngeal, oral cavity, and laryngeal SCC exists in Europe. Thus, this study was carried out to investigate HPV's impact on HNSCC patient outcomes in the Irish population, one of the largest studies of its kind using consistent HPV testing techniques. A total of 861 primary oropharyngeal, oral cavity, and laryngeal SCC (OPSCC, OSCC, LSCC) cases diagnosed between 1994 and 2013, identified through the National Cancer Registry of Ireland (NCRI), were obtained from hospitals across Ireland and tested for HPV DNA using Multiplex PCR Luminex technology based in and sanctioned by the International Agency for Research on Cancer (IARC). Both overall and cancer-specific survival were significantly improved amongst all HPV-positive patients together, though HPV status was only a significant predictor of survival in the oropharynx. Amongst HPV-positive patients in the oropharynx, surgery alone was associated with prolonged survival, alluding to the potential for de-escalation of treatment in HPV-related OPSCC in particular. Cumulatively, these findings highlight the need for continued investigation into treatment pathways for HPV-related OPSCC, the relevance of introducing boys into national HPV vaccination programs, and the relevance of the nona-valent Gardasil-9 vaccine to HNSCC prevention.
人乳头瘤病毒(HPV)感染已被确认为头颈部鳞状细胞癌(HNSCC)发病的重要病因。HPV的参与表明患者的生存率和预后较好,并提示可能需要采取不同的治疗策略。欧洲仅有一些关于口咽、口腔和喉鳞状细胞癌中HPV感染流行病学的数据。因此,本研究旨在调查HPV对爱尔兰人群中HNSCC患者预后的影响,这是同类研究中规模最大的研究之一,采用了一致的HPV检测技术。通过爱尔兰国家癌症登记处(NCRI)确定,1994年至2013年间诊断出的861例原发性口咽、口腔和喉鳞状细胞癌(OPSCC、OSCC、LSCC)病例,从爱尔兰各地的医院获取,并使用基于国际癌症研究机构(IARC)并经其批准的多重PCR Luminex技术检测HPV DNA。所有HPV阳性患者的总生存率和癌症特异性生存率均显著提高,不过HPV状态仅是口咽癌患者生存率的显著预测指标。在口咽HPV阳性患者中,单纯手术与生存期延长相关,这尤其暗示了在HPV相关的OPSCC中降低治疗强度的可能性。总体而言,这些发现凸显了继续研究HPV相关OPSCC治疗途径的必要性、将男孩纳入国家HPV疫苗接种计划的相关性以及九价加德西-9疫苗对预防HNSCC的相关性。